Multiple Myeloma | Specialty

Dr. Richter on Findings of a Study on Symptom Management in Multiple Myeloma

February 3rd 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

February 1st 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

EMA Panel Backs Carfilzomib Label Update in Myeloma

January 30th 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings

January 25th 2018

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.

Wave of Therapies Being Developed in AL Amyloidosis Space

January 25th 2018

Sandy W. Wong, MD, discusses immunoglobulin light chain amyloidosissome and recent data that have shown excitement in this landscape.

CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm

January 23rd 2018

Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.

Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple Myeloma

January 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Looking to the Future of Myeloma Care

January 23rd 2018

Improving Outcomes in Myeloma

January 23rd 2018

Immunotherapies in Myeloma

January 23rd 2018

Other Agents for Treating Myeloma

January 23rd 2018

Impact of MRD Assessment on Myeloma Treatment

January 23rd 2018

The Role of MRD Testing in Myeloma

January 23rd 2018

Adding Carfilzomib to R/R Myeloma Regimens

January 23rd 2018

Impact of Elotuzumab in R/R Myeloma Therapies

January 23rd 2018

Daratumumab-Based Regimens in R/R Myeloma

January 23rd 2018

The Role of Transplant in Myeloma

January 23rd 2018

Impact of Maintenance Therapy in Myeloma

January 23rd 2018

Upfront Combination Therapies in Myeloma

January 23rd 2018